About the 17th International Myeloma Workshop

September 12-15, 2019 at the Hynes Convention Center in Boston MA, USA

The 17^th International Myeloma Workshop under the auspices of the International Myeloma Society (IMS) is devoted to fostering scientific and clinical exchange on the latest breakthroughs in multiple myeloma and related plasma cell disorders. The conference will take place September 12-15, 2019 at the Hynes Convention Center in Boston MA, USA. Over 3,000 participants are expected to attend the 17^th IMW that will cover the latest genomic advances, insights into immune and microenvironmental dysregulation, new drug targets and agents, immunotherapeutic approaches including Car T-cell therapies, and breaking results from early and large randomized clinical trials.

The IMW 2019 will also feature a greatly expanded program of speakers and poster presenters selected from abstract submissions. Up to 40 young investigator award recipients will be selected from submitted abstracts for travel awards, and the chance to present their work and be honored at the Opening Ceremonies at the Boston Museum of Science. A black-tie event honoring IMS award recipients and workshop attendees will be held at the world-renowned Boston Museum of Fine Arts for the Closing Ceremonies. The 17^th IMW will also feature a dedicated nursing symposium covering management and treatment of multiple myeloma. Nurses and allied health professionals are invited to attend and submit abstracts. Please join us for this defining conference on myeloma and the related plasma cells disorders.

Abstract Deadlines

The deadline for abstract submissions for IMW 2019 is Friday, May 31, 2019 at 11:59 p.m. EDT.  Notifications will be made by Friday, June 28, 2019.

Abstracts for research with important late breaking results will be considered until Friday, July 17, 2019 at 11:59 p.m. EDT with notifications by Thursday, August 1, 2019.

Abstract Categories:

• Treatment of Newly Diagnosed Myeloma- Transplant Eligible
• Treatment of Newly Diagnosed Myeloma- Non-Transplant
• Treatment of Previously Treated Myeloma
• Myeloma Transplant and Maintenance Strategies
• Other Plasma Cell Disorders and Amyloidosis
• Antibody Based Treatment Approaches
• Immunotherapeutic Approaches to Myeloma
• Myeloma Novel Drug Targets
• Myeloma Novel Agents
• Myeloma Genomics
• Myeloma Signaling
• Myeloma Bone Disease
• Myeloma Microenvironment
• Myeloma MRD Assessment

Conference Organizers

Principal Organizers
	Professor Steve Treon, Chair Dana Farber Cancer Institute Harvard Medical School
	Professor Paul Richardson, Co-Chair  Dana Farber Cancer Institute Harvard Medical School
	Professor Ken Anderson, Co-Chair Dana Farber Cancer Institute Harvard Medical School
	Professor Nikhil Munshi, Co-Chair Dana Farber Cancer Institute Harvard Medical School
	Christopher Patterson Dana Farber Cancer Institute 17th IMW Secretariat

Local Organizing Committee
	Professor Noopur Raje Massachusetts General Hospital Harvard Medical School
	Professor Irene Ghobrial Dana Farber Cancer Institute Harvard Medical School
	Professor Raymond L. Comenzo John C. Davis Myeloma and Amyloid Program Tufts University School of Medicine
	Professor Vaishali Sanchorawala Amyloidosis Center Boston University Medical Center
	Dr. Ruben Carrasco Dana Farber Cancer Institute Harvard Medical School
	Professor David Avigan Beth Israel Deaconess Medical Center Harvard Medical School
	Dr. Constantine Mitsiades Dana Farber Cancer Institute Harvard Medical School